Opportunity
Simpler Grants.gov #HT942526BCRPBTA4
Dept. of the Army and Defense Health Agency solicit Breast Cancer Research Breakthrough Award Level 4
Buyer
Dept. of the Army -- USAMRAA
Posted
May 04, 2026
Respond By
September 30, 2026
Identifier
HT942526BCRPBTA4
NAICS
541715
This opportunity supports high-impact breast cancer research through a major cooperative agreement: - Government Buyer: - Dept. of the Army, US Army Medical Research Acquisition Activity (USAMRAA) - Defense Health Agency, Defense Health Agency Research and Development (DHA R&D), Defense Health Agency Contracting Activity (DHACA) - Funding Opportunity: - FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 - Approximate funding: $21 million for one award - Maximum period of performance: four years - Services Requested: - Clinical trial research services targeting breakthroughs in breast cancer prevention and treatment - Mandatory inclusion of at least two breast cancer consumer advocates in the research team - Projects may be led by a single Principal Investigator or two partnering Principal Investigators - Unique Requirements: - Research must address major challenges in breast cancer with high-impact potential - Clinical trials are required, including large-scale and comparative effectiveness studies - Application preparation, submission, review, post-award reporting, and milestone meetings are part of the scope - No specific OEMs or commercial products are requested; this is a research grant opportunity - Place of Performance and Review: - US Army Medical Research Acquisition Activity (USAMRAA) - National Capital Area (federal office context)
Description
The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports promising research with high potential to lead to breakthroughs in breast cancer. This award requires clinical trials and the inclusion of two or more breast cancer consumer advocates on the research team. The funding mechanism allows for a single Principal Investigator or two partnering PIs. The program expects to fund approximately one award with a total cost cap of $21 million and a maximum performance period of four years.